Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Conditions:   Craniopharyngioma, Child;   Craniopharyngioma;   Recurrent Craniopharyngioma Interventions:   Drug: Nivolumab;   Drug: DAY101 Sponsors:   Sabine Mueller, MD, PhD;   Bristol-Myers Squibb;   Day One Biopharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2022 Category: Research Source Type: clinical trials

MEKTOVI ® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Conditions:   Adamantinous Craniopharyngioma;   Recurrent Adamantinomatous Craniopharyngioma Intervention:   Drug: Binimetinib Oral Tablet [Mektovi] Sponsors:   Nationwide Children's Hospital;   Children's Hospital Colorado Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2022 Category: Research Source Type: clinical trials